MATCH Arm EAY131-A

**Semantic type:** Intellectual Product

**Definition:** The unique identifier assigned to the arm of the Molecular Analysis for Therapy Choice (MATCH) phase II clinical trial that is investigating treatment with afatinib in patients with solid tumors, excluding small cell and non-small cell lung carcinomas, or lymphomas that have activating EGFR gene mutations and progression following standard treatment.

**Synonyms:** - A - EAY131-A